Entropy Technologies LP Purchases 38,783 Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Key Points

• Entropy Technologies LP increased its stake in DENTSPLY SIRONA Inc. by 116.7%, acquiring an additional 38,783 shares and bringing its total holdings to 72,002 shares valued at approximately $1,076,000.
• Several institutional investors have significantly raised their positions in DENTSPLY SIRONA, including AQR Capital Management, which increased its stake by 245.1% in the fourth quarter.
• DENTSPLY SIRONA's stock has seen a price decline, with analysts adjusting target prices downwards, and the current consensus rating is a "Hold" with a price target of $18.64.

Entropy Technologies LP raised its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 116.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 72,002 shares of the medical instruments supplier's stock after acquiring an additional 38,783 shares during the quarter. Entropy Technologies LP's holdings in DENTSPLY SIRONA were worth $1,076,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of XRAY. AQR Capital Management LLC raised its stake in shares of DENTSPLY SIRONA by 245.1% in the fourth quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier's stock worth $54,389,000 after buying an additional 2,054,767 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of DENTSPLY SIRONA by 18.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock worth $238,186,000 after buying an additional 1,975,404 shares during the period. Invenomic Capital Management LP raised its stake in shares of DENTSPLY SIRONA by 201.0% in the fourth quarter. Invenomic Capital Management LP now owns 2,639,161 shares of the medical instruments supplier's stock worth $50,091,000 after buying an additional 1,762,428 shares during the period. Lazard Asset Management LLC raised its stake in shares of DENTSPLY SIRONA by 23.0% in the fourth quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier's stock worth $152,678,000 after buying an additional 1,505,928 shares during the period. Finally, Voloridge Investment Management LLC bought a new position in shares of DENTSPLY SIRONA in the fourth quarter worth about $24,571,000. Institutional investors own 95.70% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on XRAY shares. Barrington Research set a $18.00 target price on DENTSPLY SIRONA and gave the stock an "outperform" rating in a research report on Friday. Piper Sandler cut their target price on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Morgan Stanley cut DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 target price for the company. in a research report on Tuesday, April 15th. Stifel Nicolaus cut their target price on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating for the company in a research report on Friday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of DENTSPLY SIRONA in a research report on Monday, July 21st. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, DENTSPLY SIRONA presently has a consensus rating of "Hold" and a consensus price target of $18.64.

DENTSPLY SIRONA Price Performance

Shares of DENTSPLY SIRONA stock opened at $12.52 on Tuesday. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -2.64, a price-to-earnings-growth ratio of 0.80 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69. The stock has a 50 day moving average price of $15.64 and a 200-day moving average price of $15.82. DENTSPLY SIRONA Inc. has a one year low of $12.16 and a one year high of $27.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to analysts' expectations of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%. The company's quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 EPS. Equities analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Stockholders of record on Friday, September 26th will be issued a $0.16 dividend. The ex-dividend date is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 5.1%. DENTSPLY SIRONA's payout ratio is -13.50%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.